Publications by authors named "Michael Schlag"

Claim this Profile
E
Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015.
Christoph Sarrazin, Peter Buggisch, Stefan Mauss, Tobias Müller, Tim Zimmermann, Michael Schlag

Z Gastroenterol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications.
Fiona Marra, Christoph Höner Zu Siederdissen, Saye Khoo, David Back, Michael Schlag

Br J Clin Pharmacol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease.
Christophe Hézode, Piero L Almasio, Stefan Bourgeois, Peter Buggisch, Ashley Brown, Michael Schlag

Liver Int· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response.
Tarik Asselah, Christophe Moreno, Christoph Sarrazin, Michael Gschwantler, Graham R Foster, Michael Schlag

PLoS One· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1).
Tarik Asselah, Christophe Moreno, Christoph Sarrazin, Michael Gschwantler, Graham R Foster, Michael Schlag

PLoS One· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection.
Gianpiero D'Offizi, Calogero Cammà, Chiara Taibi, Michael Schlag, Karin Weber

New Microbiol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reasons for not starting antiretroviral therapy in HIV-1-infected individuals: a changing landscape.
Jan Fehr, Dunja Nicca, Jean-Christophe Goffard, David Haerry, Michael Schlag

Infection· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region.
Christoph Sarrazin, Erkki Lathouwers, Monika Peeters, Bjorn Daems, Annemie Buelens, Michael Schlag

Antiviral Res· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic burden of late presentation in HIV disease in Austria: a comparison of the initial costs imposed by advanced HIV disease vs. non-late presentation.
Katharina Grabmeier-Pfistershammer, Armin Rieger, Thomas Schröck, Michael Schlag

Wien Klin Wochenschr· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a gamma-aminobutyric acid(A) receptor antagonistic effect.
Roman Furtmüller, Michael G Schlag, Michael Berger, Rudolf Hopf, Sigismund Huck

J Pharmacol Exp Ther· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficient carboplatin single therapy in a mouse model of human testicular nonseminomatous germ cell tumor.
Seyedhossein Aharinejad, Melanie Fink, Hojatollah Abri, Stephan Nedwed, Michael G Schlag

J Urol· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis